logo-loader
viewCellmid Limited

Cellmid partners with EAS Advisors for U.S. expansion

This is a strong endorsement of Cellmid's business model as EAS Advisors has a strong track record with ASX listed companies in the U.S. market. Cellmid is also looking to out-license its proprietary active ingredients to other brand owners.

au_united_states350_55caae03d7ecd.jpg

Cellmid Limited (ASX:CDY) has partnered with EAS Advisors to support expansion of its hair growth products into the U.S. hair care market, which reached sales of US$11.6 billion in 2014.

Cellmid lays claim as the only company globally with an FGF5 inhibitor hair growth product on the market.
   
New York-based investment advisory firm EAS was founded by Eddie Sugar in 2008.

Cellmid reported strong sales growth for FY2015 with its sales and advertising campaign expected to further grow revenues of its évolis® branded FGF5 inhibitor consumer products in Australia.

It plans to replicate its strategy of a retail distribution model based initially on pharmacies in the U.S where there are more than 20,000 pharmacies.

In addition, its proprietary active ingredients are suitable for out-licensing to other brand owners either as active ingredients or fully formulated products.

EAS will work with Cellmid to provide strategic support in the company’s U.S. growth activities and exposure to local investors.

Maria Halasz, chief executive officer, commented:

“EAS has a successful track record assisting Australian companies maximise their U.S. growth potential. We are delighted to be one of the select companies they decided to work with.”


Recent Activity


In the fourth quarter of FY2015, Cellmid’s consumer health business delivered sales of $960,000 bringing full-year sales up to $1.84 million for its FGF5 inhibitor hair growth products.

This is up 63% on the last financial year.

It also lays the foundation for FY2016 sales to significantly exceed the previous year.

In July, it raised $4 million through an oversubscribed placement of shares priced at $0.03 to leverage increasing sales and further expand its growth in Australia and internationally.


Analysis

The agreement with EAS Advisors will help drive sales of Cellmid’s hair growth products in the major U.S. market.

Sales in Australia already expected to grow given that the company has yet to ship products to 70% of its planned distribution while its GP sales force only started in May.

In Japan, it has broadened sales channels to five from two. This includes private label, duty free retail, TV shopping, export and website sales.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Cellmid Limited

Price: 0.12 AUD

ASX:CDY
Market: ASX
Market Cap: $15.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

3 min read